Status:
RECRUITING
Brain Activity Associated With Inhibition of Action in Attention-deficit
Lead Sponsor:
University Hospital, Toulouse
Collaborating Sponsors:
Centre National de la Recherche Scientifique, France
Conditions:
Attention Deficit
Hyperactivity Disorder
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
Inhibitory control allows individuals to suppress unwanted actions and to resist irrelevant stimuli. It is thought to be a core deficit in Attention-deficit/hyperactivity disorder (ADHD). The present ...
Detailed Description
ADHD is a psychiatric disorder characterized by symptoms of inattention, hyperactivity, and impulsivity (DSM-V, 2013). An impairment of inhibitory control has been suggested as the primary deficit in ...
Eligibility Criteria
Inclusion
- Age between 18 and 50,
- Visual, auditory (authorized apparatus), motor skills suitable for the proper realization of neuropsychological tests,
- Being right-handed,
- Free, informed and written consent signed by the participant and the investigator
- Person affiliated or beneficiary of a social security scheme.
- For the ADHD group:
- Diagnosis of ADHD according to DSM-V criteria (APA, 2013),
- For the patient control group:
- • Patient who consulted for a cognitive complaint and for whom the diagnosis of ADHD was rejected according to the criteria of DSM-V (APA, 2013).
Exclusion
- General or progressive neurological disease resulting in cognitive impairment (multiple sclerosis, Parkinson's disease, stroke, etc.),
- Insufficient linguistic level in French to participate in neuropsychological assessment,
- Patient placed under judicial protection or under another protective regime,
- Severe depression according to DSM-V criteria (APA, 2013),
- Autism spectrum disorder, developmental coordination disorder.
- For the healthy voluntary control group:
- Presence of a cognitive complaint or pathology which may impair his cognitive functions
Key Trial Info
Start Date :
March 17 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04768556
Start Date
March 17 2021
End Date
December 1 2024
Last Update
May 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toulouse Purpan University Hospital
Toulouse, France, 31000